1Smyth JF,Gourley C,Walker G et al.Antiestrogen therapy is active in selected ovarian cancer cases:the use of letrozole in estrogen receptor-positive patients[J].Clin Cancer Res,2007,13(12):3617-3622.
2Bowman A,Gabra H,Langdon SP et al.CA125 response is associated with estrogen receptor expression in a phaseⅡtrial of letrozole in ovarian cancer:identification of an endocrine-sensitive subgroup[J].Clin Cancer Res,2002,8(7):2233-2239.
3Cunat S,Rabenoelina F,Daures JP et al.Aromatase expres-sion in ovarian epithelial cancer[J].J Steroid Biochem MolBiol,2005,93(1):15-24.
4Bell DA.Origins and molecular pathology of ovarian cancer[J].Modern Pathology,2005,18:s19-s32.
5Marta Keith Bechtel,Benjamin Bonavida.Inhibitory effects of17β-estradiol and progesterone on ovarian carcinoma cell pro-liferation:a potential role for inducible nitric oxide synthase[J].Gynecologic Oncology,2001,82(1):127-138.
6Lucia MB,Golotta C,Rutella S et al.Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity[J].J Acquir Immune Defic Syndr,2005,39(5):635-637.
